GET THE APP

A Clinical Study to Determine the Efficacy of Pramehhara Kwatha in the Management of Madhumeha W.S.R. to Type II Diabetes Mellitus | Abstract
Logo

International Journal of Medical Research & Health Sciences (IJMRHS)
ISSN: 2319-5886 Indexed in: ESCI (Thomson Reuters)

Abstract

A Clinical Study to Determine the Efficacy of Pramehhara Kwatha in the Management of Madhumeha W.S.R. to Type II Diabetes Mellitus

Author(s):Anant Bhardwaj*

The present is an era of rapid modernization. Due to sedentary lifestyle and faulty dietary habits, humans are becoming more vulnerable to several metabolic disorders. Preameha is one of them which is caused by association of vitiated tridoshas and morbid Meda, Rakta, Shukra, Ambu, Vasa, Lasika, Majja, Rasa, Oja and Mamsa dhatus. In modern science, it resembles the symptomatology of type II diabetes mellitus which is caused by inadequate insulin production, improper insulin action, or both. In 20th century Dr. Gananath Sen and others have expounded about the theory that Madhumeha is Dhatwagni mandya vikara which can be correlated to diabetes mellitus. Type 2 diabetes mellitus may be included under the broad spectrum of prameha described in Ayurvedic classics. Prameha is considered as Mahagada by Ayurvedic Acharayas. Mahagada are diseases having chronicity with involvement of Tridoshas, multiple Dhatus and Strotases affecting vital organs and thus rendering them difficult to treat. From Ayurvedic point of view, Prameha seems to stem from metabolic derangements at different levels caused either due to genetic factor or due to Apathya Ahara and Vihara. The prevalence of diabetes in high socio-economic population of rural areas is more and in rural areas of all states of India, diabetes was more prevalent in individuals of higher SES. In the next 20 years, it is expected that the prevalence of diabetes in adults-of which type 2 DM is becoming more prevalent. A large portion of this rise will take place in developing nations, where the majority of patients are between the ages of 45 and 64. In 2011, 366 million individuals were expected to have DM; by 2030, this number will have increased to 552 million. It is a potential signal for several comorbidities like hypertension, coronary artery disease, renal diseases etc.


Select your language of interest to view the total content in your interested language

Archive
Scope Categories
  • Clinical Research
  • Epidemiology
  • Oncology
  • Biomedicine
  • Dentistry
  • Medical Education
  • Physiotherapy
  • Pulmonology
  • Nephrology
  • Gynaecology
  • Dermatology
  • Dermatoepidemiology
  • Otorhinolaryngology
  • Ophthalmology
  • Sexology
  • Osteology
  • Kinesiology
  • Neuroscience
  • Haematology
  • Psychology
  • Paediatrics
  • Angiology/Vascular Medicine
  • Critical care Medicine
  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Infectious Diseases and Vaccinology
  • Hepatology
  • Geriatric Medicine
  • Bariatrics
  • Pharmacy and Nursing
  • Pharmacognosy and Phytochemistry
  • Radiobiology
  • Pharmacology
  • Toxicology
  • Clinical immunology
  • Clinical and Hospital Pharmacy
  • Cell Biology
  • Genomics and Proteomics
  • Pharmacogenomics
  • Bioinformatics and Biotechnology